cardiovascular-agents and Agranulocytosis

cardiovascular-agents has been researched along with Agranulocytosis* in 4 studies

Trials

1 trial(s) available for cardiovascular-agents and Agranulocytosis

Article	Year
Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study. Clinical pharmacology and therapeutics, 1991, Volume: 49, Issue:3 The risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs were estimated in a population-based case-control study conducted in Israel and Europe (total population, 23 million). Cardiovascular drug use in the week before onset of illness was compared between 270 patients hospitalized with agranulocytosis and 1870 hospitalized control subjects. Propranolol (relative risk, 2.5), dipyridamole (3.8), digoxin (2.5), and acetyldigoxin (9.9) were significantly associated with agranulocytosis. The excess risks attributable to these drugs ranged from one to three cases per 10 million persons exposed for up to 1 week. Increased risks were also observed for cinepazide (used by six cases and no control subjects), procainamide (7, 1), and aprindine (5, 1); based on crude relative risk estimates, the excess risks for the latter two drugs were approximately three per million persons exposed for up to 1 week. The use of cardiovascular drugs in a 5-month period ending 1 month before hospital admission was compared between 152 patients with aplastic anemia and 2180 control subjects. Furosemide was the only significantly associated drug (relative risk, 3.1); the excess risk attributable to any exposure in a 5-month interval was 1.7 per million. Topics: Adrenergic beta-Antagonists; Agranulocytosis; Anemia, Aplastic; Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiac Glycosides; Cardiovascular Agents; Case-Control Studies; Diuretics; Europe; Humans; Israel; Nitrates; Risk Factors; Vasodilator Agents	1991

Article

Year

Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study.

Clinical pharmacology and therapeutics, 1991, Volume: 49, Issue:3

The risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs were estimated in a population-based case-control study conducted in Israel and Europe (total population, 23 million). Cardiovascular drug use in the week before onset of illness was compared between 270 patients hospitalized with agranulocytosis and 1870 hospitalized control subjects. Propranolol (relative risk, 2.5), dipyridamole (3.8), digoxin (2.5), and acetyldigoxin (9.9) were significantly associated with agranulocytosis. The excess risks attributable to these drugs ranged from one to three cases per 10 million persons exposed for up to 1 week. Increased risks were also observed for cinepazide (used by six cases and no control subjects), procainamide (7, 1), and aprindine (5, 1); based on crude relative risk estimates, the excess risks for the latter two drugs were approximately three per million persons exposed for up to 1 week. The use of cardiovascular drugs in a 5-month period ending 1 month before hospital admission was compared between 152 patients with aplastic anemia and 2180 control subjects. Furosemide was the only significantly associated drug (relative risk, 3.1); the excess risk attributable to any exposure in a 5-month interval was 1.7 per million.

Topics: Adrenergic beta-Antagonists; Agranulocytosis; Anemia, Aplastic; Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiac Glycosides; Cardiovascular Agents; Case-Control Studies; Diuretics; Europe; Humans; Israel; Nitrates; Risk Factors; Vasodilator Agents

1991

Other Studies

3 other study(ies) available for cardiovascular-agents and Agranulocytosis

Article	Year
[Effect of hydergine on blood eosinopenia produced by light; preliminary report]. Acta medica Academiae Scientiarum Hungaricae, 1958, Volume: 12, Issue:3-4 Topics: Agranulocytosis; Cardiovascular Agents; Eosinophils; Ergoloid Mesylates; Ergot Alkaloids; Humans; Leukocyte Count; Oxytocics	1958
[Experimental research on eosinopenia caused by glucose and insulin]. Archivio per le scienze mediche, 1954, Volume: 98, Issue:5 Topics: Agranulocytosis; Barbiturates; Cardiovascular Agents; Eosinophils; Ergot Alkaloids; Glucose; Insulin; Leukocyte Count	1954
The effect of hexamethonium chloride on the eosinopenic response during stress in rats. Acta endocrinologica, 1953, Volume: 14, Issue:1 Topics: Agranulocytosis; Animals; Cardiovascular Agents; Eosinophils; Hexamethonium; Leukocyte Count; Mental Disorders; Muscle Relaxants, Central; Rats; Stress, Physiological	1953